Diagnosis and Treatment of Diffuse Interstitial Lung Diseases;Diagnóstico y Tratamiento de las Enfermedades Pulmonares Intersticiales Difusas

Archivos de Bronconeumologia

Volumn 39, Issue 12, 2003, Pages 580-600

  Xaubet, A ^a   Ancochea, J ^b   Blanquer, R ^c   Montero, C ^d   Morell, F ^e   Rodriguez Becerra E ^f   Sueiro, A ^g   Villena, V ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID;

CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; LUNG TRANSPLANTATION; REVIEW; SPIROMETRY; THORAX RADIOGRAPHY;

EID: 0346271814     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13054364     Document Type: Review

References (88)

1. Olivieri D, Du Bois RM. Interstitial lung diseases. European Respiratory Monograph 2000;5(monopgraph 14).
2. Selman M. Neumopatías intersticiales difusas. México DF: Médica Panamericana, 1996.
3. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
4. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
5. Demetds M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J 2001;18 (Suppl 32):2S-16S.
6. Schwarz MI. Clinical overview of interstitial lung disease. En: Schwarz MI, King TE, editors. Interstitial lung disease. St. Louis: Mosby Year Book, 1998; p. 2-30.
7. Cushley M, Davison A, Du Bois RM, Flower C, Greening A, Ibrahim N, et al. BTS Guidelines. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999;54(Suppl 1):1-30.
8. Morell F, Levy G, Orriols R, Ferrer J, De Gracia J, Sampol G. Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis. Chest 2002;121:1239-44.
9. Chetta A, Aiello M, Foresi A, Marango E, D'Ippolito R, Castagnaro A, et al. Relatioship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:170-5.
10. ATS statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
11. Castella J, Ancochea J, Llorente L, Puzo C, Sanchis J, Sueiro A, et al. Normativa SEPAR: lavado broncoalveolar. Arch Bronconeumol 1997;33:515-26.
12. Panos RJ, Mortenson RL, Niccoli SA, King T. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88:396-404.
13. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intens Care Med 2001;27:1868-74.
14. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
15. International guidelines for selection of lung transplant candidates. Am J Respir Crit Care 1998;158:335-40.
16. Trulock EP. Lung transplantation: state of the art. Am J Resp Crit Care 1998;155:789-818.
17. De Meester J, Smits JM, Persijn G, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the eurotransplant experience. J Heart Lung Transplant 2001;20:518-24.
18. Mogulkoc N, Brutsche M, Bishop P, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Resp Crit Care 2001;164:103-8.
19. Hosenpud J, Bennett L, Keck B, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351:24-7.
20. Johnson BA, Duncan SR, Ohori NP, Paradis IL, Yousem SA, Grgurich WF, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Resp Dis 1993;148:1373-7.
21. De Vries J, Kessels BLJ, Drent M. Quality of life of idiopathic pulmonary fibrosis. Eur Respir J 2001;17:954-61.
22. Xaubet A, Agustí C, Luburich P, Roca J, Monton C, Ayuso MC, et al. Pulmonary function tests and CT scans in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:431-46.
23. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance and pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15.
24. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypothese about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51.
25. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-25.
26. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:1171-81.
27. Xaubet A, Agustí C, Luburich P, Roca J, Ayuso MC, Marrades RM, et al. Is it necessary to treat all patients with idiopathic pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis 2001;18:289-95.
28. Ziesche R, Hofbauer E, Wittmann K, Petrov V, Block LH. A preliminary study of long term treatment with interferon gamma 1-b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9.
29. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-83.
30. Lazor R, Vandevenne A, Pelletier A, Lecrec P, Court-Fortune I, Cordier JF. Cryptogenic organizing pneumonia. Am J Respir Crit Care Med 2000;162:571-7.
31. Bouros D, Nicholson AC, Polychronopoulos V, Du Bois RM. Acute interstitial pneumonia. Eur Respir J 2000;15:412-8.
32. Ichikado R, Suga M, Müller NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia. Comparison of high-resolution computed tomography findings between survivors and non-survivors. Am J Respir Crit Care Med 2002;165:1551-6.
33. Jason V, Brown KK, Cool CD, Young DA, Cherniak RM, King TE, et al. Acute interstitial pneumonitis: case series and review of the literature. Medicine (Baltimore) 2000;79:369-78.
34. Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001;18 (Suppl 32):56S-68S.
35. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1994;336:1224-34.
36. Mañá J, Badrinas F, Morera J, Fite E, Manresa F, Fernández-Nogués F. Sarcoidosis in Spain. Sarcoidosis 1992;9:118-22.
37. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, Du Bois R, et al Statement on sarcoidosis. Am J Respir Crit Care Med 1999;160:736-55.
38. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA. A Case Control Etiologic Study of Sarcoidosis (ACCES) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.
39. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-47.
40. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis. A systematic review. JAMA 2002;287:1301-7.
41. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids. The six phases of treatment. Chest 1999;115:1158-65.
42. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997;14:121-30.
43. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999;54:742-6.
44. Müller J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117-22.
45. Gibson GJ. Sarcoidosis: old and new treatments. Thorax 2001;56:336-9.
46. Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patients with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:10-7.
47. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J 2001;18(Suppl 32):69S-80S.
48. Cheema GS, Quismorio FP. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000;6:424-9.
49. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5.
50. Deheinzelin D, Capelozzi VL, Kairalla RA, Filho JVB, Saldiva PHN, De Carvalho CRR. Interstitial lung disease in primary Sjögren's syndrome: clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996;154:794-9.
51. Schmidt WA, Wetzel W, Friedländer R, Lange R, Sorensen HF, Lichey HJ. Clinical and serological aspects of patients with anti Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000;19:371-7.
52. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relation to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
53. Miyake S, Ohtano Y, Sawada M, Inase N, Miyazaki V, Takano S, et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:128-33.
54. White B, Moore WC, Wigley FM, Xiao HO, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
55. Patel AM, Ryu JH, Reed CE. Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol 2001:108:661-70.
56. Bourke SJ, Dalphin JC, Boyd G, McSharry C, Baldwin CI, Calvert JE. Hypersensitivity pneumonitis: current concepts. Eur Respir J 2001;18(Suppl 32):81S-92S.
57. Hinojosa M, Frag J, De la Hoz B, Sueiro A. Hypersensitivity pneumonitis in workers exposed to asparto grass (stipa tenacissima fibers). J Allergy Clin Immunol 1996;95:985-91.
58. Morell F, Curull V, Orriols R, De Gracia J. Skin tests in bird breeder's disease. Thorax 1986;41:538-41.
59. Ramírez-Venegas A, Sansores RH, Pérez-Padilla R, Carrillo G, Selman M. Utility of a provocation test for diagnosis of chronic pigeon breeder's disease. Am J Respir Crit Care Med 1998;158:862-9.
60. Schuyler M, Cormier Y. The diagnosis of hypersensitivity pneumonitis. Chest 1997;111:534-6.
61. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001;13:242-8.
62. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug-induced infiltrative lung disease. Eur Respir J 2001;18(Suppl 32):93S-100S.
63. Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med 2002;96:1-6.
64. Roman A, Aristizábal D, Pallisa E, Majó J, Iscar M, Monforte V, et al. Linfangioleiomiomatosis: estudio de 15 pacientes. Med Clin (Barc) 2000;115:98-102.
65. Kelly J, Moss J. Lymphangioleiomyomatosis. Am J Med Sci 2001;321:17-25.
66. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000:55:1052-7.
67. Matsui K, Tatsuguchi A, Valencia J, Yu Z, Bechtle J, Beasley MB, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000;31:1242-8.
68. Moss J, Ávila NA, Barnés PM, Litzenberger RA, Bechtle J, Brooks PG, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001;164:669-71.
69. Miller WT. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000;343:1656-60.
70. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999;85:2278-90.
71. Morell F, Reyes L, Majó J, Orriols R, Román A. Histiocitosis de células de Langerhans. Estudio clínico y evolución a largo plazo de 21 pacientes. Med Clin (Barc) 2000;115:60-4.
72. 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis. J Nucl Med 2000;41:1808-12.
73. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002:346:484-90.
74. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2002;166:215-35.
75. Chesnutt MS, Nuckton TJ, Golden J, Folkesson HG, Matthay MA. Rapid alveolar epithelial fluid clearance following lung lavage in pulmonary alveolar proteinosis. Chest 2001;120:271-4.
76. Ben-Abraham R, Greenfeld A, Rozenman J, Ben-Dov I. Pulmonary alveolar proteinosis: step-by-step perioperative care of whole lung lavage procedure. Heart Lung 2002;31:43-9.
77. Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doule IR, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001;163:524-31.
78. Chan ED, Morales DV, Welsh CH, McDermott MT, Schwarz ML. Calcium deposition with or without bone formation in the lung. Am J Respir Crit Care Med 2002;165:1654-69.
79. Senyigit A, Yaramis A, Gurkan F, Kirbas G, Buyukbayram H, Nazaroglu H, et al. Pulmonary alveolar microlithiasis: a rare familial inheritance with report of six cases in a family. Contribution of six new cases to the number of case reports in Turkey. Respiration 2001;68:204-9.
80. Hoshino H, Koba H, lnomata S, Kurokawa K, Morita Y, Yoshida K, et al. Pulmonary alveolar microlithiasis: high-resolution CT and MR findings. J Comput Assist Tomogr 1998;22:245-8.
81. rd ed. Hamilton: BC Decker, 1988; p. 559-96.
82. a ed. Madrid: Harcourt, 2000; p. 950-4.
83. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977;86:405-14.
84. Philit F, Etienne-Mastroianni B, Parrot A, Guerin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002;166:12135-9.
85. Churg A, Green FHY. Pathology of occupational lung disease. Baltimore: Willians & Wilkins, 1998.
86. Parkes WR. Occupational lung disorders. Oxford: Butterworth-Heinemann, 1994.
87. Hendrick DJ, Burge PS, Beckett WS, Churg A. Occupational disorders of the lung. London: WB Saunders, 2002.
88. Camus PH, Colby TV. The lung in inflammatory bowel disease. Eur Respir J 2000;15:5-10.